Global Regulatory Enablement Hansoh Bio is actively engaging international regulatory support partners to navigate approvals outside China, including partnerships with Veristat. This signals readiness to scale globally. Sales opportunities include offering regulatory affairs outsourcing, global trial management, and regulatory intelligence to accelerate filings in the US and EU for ADCs and oncology assets.

Oncology R&D Acceleration The company is prioritizing R&D with a focus on oncology and metabolic diseases and has showcased data for HS-20089 at industry forums. This creates demand for clinical development services, biomarker strategy, data management, and potential manufacturing support for later-stage trials and commercialization.

ADC Collaboration Ecosystem A track record of ADC-related partnerships exists with Biotheus for EGFR/cMET bispecific ADCs, a GSK exclusive license for HS-20089, and a collaboration with TiumBio for TU2670. This opens opportunities for licensing or co-development discussions, ADC-focused CRO/CDMO support, analytical characterization, and manufacturing and clinical trial supply.

US Presence Being based in Rockville, Maryland with a mid-size team offers a nimble US-based partner for CROs, CMOs, and clinical operations. Propose outreach for contract manufacturing, fill-finish capabilities, cold chain logistics, and local regulatory filing support to accelerate North American activities.

Partnership Driven Growth Hansoh Bio’s strategy leans on partnerships to advance oncology assets and global market access, complemented by substantial financing for R&D. Potential sales angles include licensing out late-stage assets, regional distribution deals, and market access or payer strategy services to monetize a diverse portfolio.